JAK1 and prostate carcinoma: Agarwal and colleagues have also found that the combination of the Jak1 inhibitor and silibinin (an active constituent of silymarin) is able to reduce STAT3 phosphorylation and to activate caspase-9 and caspase-3, thus leading to the apoptosis of prostate cancer DU145 cells [49].